A real-world study conducted by Duke Health provides key insights into the safety of lecanemab, an approved treatment for early-stage Alzheimer's disease. The drug aims to slow disease progression by clearing a specific protein from the brain. Researchers tracked over 230 patients between 2023 and 2025 for up to 396 days to compare real-world outcomes with clinical trial data.
According to results published in Neurology Open Access, approximately 80% of patients remained on the medication for at least one year. However, about 21% discontinued treatment, mainly due to adverse reactions. Researchers focused heavily on a side effect known as Amyloid Related Imaging Abnormalities, or ARIA, which involves brain swelling or bleeding:
- Around 24.3% of patients experienced ARIA during their treatment.
- Patients carrying two copies of the high-risk APOE ε4 gene were four times more likely to develop ARIA.
- Developing ARIA did not negatively impact changes in cognitive test scores at 12 months.
While current tests cannot reliably predict who will develop ARIA, combining blood tests with MRI scans shows potential. Additionally, Duke Health evaluated an artificial intelligence tool to detect subtle brain changes earlier. Although lecanemab does not cure Alzheimer's or reverse memory loss, doctors emphasize that slowing disease progression helps patients stay independent longer and gives families extra time.
Difficult words
- progression — the process of developing or advancing over time
- discontinue — to stop doing, using, or providing somethingdiscontinued
- adverse — harmful, dangerous, or causing unpleasant results
- cognitive — connected with thinking, understanding, learning, and remembering
- evaluate — to judge or calculate the quality or valueevaluated
- subtle — small and difficult to notice or describe
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is it important to study the real-world effects of medical treatments after clinical trials are completed?
- How might slowing down a disease's progress, rather than curing it, benefit patients and their families?
- What potential benefits or concerns do you see in using artificial intelligence to detect brain changes early?
